Recent studies have linked ISO as a protective factor against hepatic steatosis and NAFLD for its ability to increase β-oxidation and inhibit lipogenesis in the liver [72, 81], alleviate insulin resistance, and suppress inflammation [25], mostly through activating protein kinase (AMPK) and peroxisome proliferator-activated receptor alpha (PPAR-α) [75, 77]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.